Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03965481 · ClinicalTrials.gov registry record · NA

PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer

A NA study of Ovarian Carcinoma and Malignant Ovarian Neoplasm, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
NA
Development phase
21
Enrollment target
1
Study location

NCT03965481: Active NA study of Ovarian Carcinoma and Malignant Ovarian Neoplasm, sponsored by M.D. Anderson Cancer Center.

NCT03965481 is a NA study of Ovarian Carcinoma and Malignant Ovarian Neoplasm that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 21 participants, below the 3,244-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03965481, a NA study of Ovarian Carcinoma and Malignant Ovarian Neoplasm, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

This trial studies how well positron emission tomography/magnetic resonance (PET/MR) versus contrast enhanced computerized tomography (CECT) scans work in locating ovarian cancer tumors in patients with known or suspected ovarian cancer. PET, MR, and CECT scans use different methods to create images of areas inside the body. This trial is being done to see if PET/MR scans may help doctors locate ovarian cancer tumors, predict how well these tumors may be removed during surgery, and predict how patients respond to platinum-based chemotherapies compared to standard of care CECT scans.

Primary Outcome

Lesion detection accuracy will be summarized using frequencies and percentages by modality. McNemar's test will be used to compare accuracies between positron emission tomography (PET)/magnetic resonance (MR) and contrast enhanced computerized tomography (CECT). Other diagnostic metrics (sensitivity, specificity, positive predictive value, and negative predictive value) will be estimated along with 95% confidence intervals. Logistic regression model will be used to assess effect of patient and t

Interventions

  • PROCEDURE Magnetic Resonance Imaging
  • PROCEDURE Positron Emission Tomography
  • RADIATION Dynamic Enhanced CT

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 2018-05-12
Est. Completion 2027-04-30
Phase NA
M.D. Anderson Cancer Center

2,692 total trials

What the registry record for NCT03965481 still lists

NCT03965481 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 3,244-participant average among 35 other Ovarian Carcinoma trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Ovarian Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Magnetic Resonance Imaging is the first listed.

NCT03965481 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT03965481 about?

NCT03965481 is a clinical study titled "PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer". This trial studies how well positron emission tomography/magnetic resonance (PET/MR) versus contrast enhanced computerized tomography (CECT) scans work in locating ovarian cancer tumors in patients with known or suspected ovarian cancer. PET, MR, and CECT scans use different methods to create images...

What is the current status of trial NCT03965481?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 21 participants. The study started on 2018-05-12. Estimated completion is 2027-04-30.

What conditions does trial NCT03965481 study?

This clinical trial studies the following conditions: Ovarian Carcinoma, Malignant Ovarian Neoplasm.

What interventions are being tested in trial NCT03965481?

The interventions under investigation include: Magnetic Resonance Imaging (PROCEDURE), Positron Emission Tomography (PROCEDURE), Dynamic Enhanced CT (RADIATION).

Who is sponsoring clinical trial NCT03965481?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03965481 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ovarian Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03965481's enrollment target sits among peer trials

21 32nd of 35 higher than 4 of 35 other Ovarian Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ovarian Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03965481, the US trial registry maintained by the National Library of Medicine. NCT03965481 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.